Screener
Regeneron Pharmaceuticals REGN Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other noncurrent liabilities | 2,281.6 | 2,018.8 |
| Total liabilities | 10,019.2 | 9,301.8 |
| Stockholders' equity: | ||
| Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none | — | — |
| Class A Stock, convertible, par value $.001 per share; 40.0 shares authorized; shares issued and outstanding - 1.8 in 2026 and 2025 | — | — |
| Common Stock, par value $.001 per share; 320.0 shares authorized; shares issued - 138.0 in 2026 and 137.6 in 2025 | 0.1 | 0.1 |
| Additional paid-in capital | 14,700.6 | 13,995.0 |
| Retained earnings | 37,621.4 | 35,797.1 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's preferred stock par value per share?
- Regeneron Pharmaceuticals (REGN) reported preferred stock par value per share of $0.01 in Q2 2026.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about Regeneron Pharmaceuticals's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude